Seema Verma Heightens Scrutiny and Oversight of Facility Antipsychotic Use

Lisa Volk and Nancy Leveille in Clinical & Quality

Our national association, AHCA, learned last night that Seema Verma is calling the CEOs of some nursing home chains about their antipsychotic use. She has made two calls to date and is scheduling others. CMS has flagged facilities on the “late adopter list” into group 1 and group 2 facilities that also have received a citation for inappropriate use of psychotropic medications or unnecessary medications (F605 use medications as restraints, F744 dementia care, or F758 unnecessary medications) on ANY survey from Jan. 1, 2016 - Jan. 15, 2019 with a scope and severity D or higher. They have sent this list to the state survey agencies to conduct surveys. If any of these facilities are cited again for one of those three tags, CMS will impose a CMP and DPNA immediately (within 2 days for IJs and 15 days for non-IJs of the survey). The QSO memo is attached for your review.

AHCA received the list of group 1 and group 2 facilities last week through a Freedom of Information Act (FOIA) request. NYSHFA will be receiving that information and will notify you if you are on the late adopter list and which facilities are in group 1 or group 2 and are subject to heightened survey scrutiny and immediate DPNA. 

I have attached a flyer highlighting a package of tools to help your facilities lower their unnecessary antipsychotic use. 


Lisa Volk, RN, B.P.S., LNHA
Director, Clinical & Quality Services
518-462-4800 x15

Nancy Leveille, RN, MS
Executive Director
518-462-4800 x20